CRISPR Therapeutics AG CRSP

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.

We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine. Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body.

Last close 49.39 2026-10-23
Market cap $4.78B 2026-06-30 share count
52-week range 44.12 - 65.98

Valuation FY2025 figures against the last close

P/S1,360.6x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-6.47

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $3.5M$37.3M$371.2M$1.2M$915.0M$719.0K$289.6M$3.1M$41.0M$5.2M
R&D $284.8M$310.2M$387.3M$461.6M$340.6M$221.4M$179.4M$113.8M$69.8M$42.2M
SG&A $73.5M$73.0M$76.2M$102.5M$99.7M$85.7M$63.5M$48.3M$35.8M$31.1M
Total operating expenses $668.1M$503.9M$593.7M$674.4M$541.4M$355.2M$242.8M$162.1M$105.6M$73.3M
Operating income -$664.6M-$466.6M-$222.5M-$673.2M$373.5M-$354.4M$46.7M-$158.9M-$64.6M-$68.1M
Pre-tax income -$578.0M-$362.7M-$150.7M-$650.5M$379.5M-$348.1M$67.3M-$164.4M-$66.6M-$22.7M
Income tax $3.6M$3.6M$2.9M$325.0K$1.9M$809.0K$448.0K$553.0K$1.7M$484.0K
Net income -$581.6M-$366.3M-$153.6M-$650.2M$377.7M-$348.9M$66.9M-$165.0M-$68.4M-$23.2M
EPS, basic -6.47-4.34-1.94-8.364.97-5.291.23-3.44-1.71—
EPS, diluted -6.47-4.34-1.94-8.364.70-5.291.17-3.44-1.71-1.89
Shares, diluted (wtd. avg.) 89.9M84.4M79.2M77.7M80.4M65.9M56.9M48.0M40.1M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $347.6M$298.3M$389.5M$211.9M$923.0M$1.17B$943.8M$456.6M$239.8M$315.5M
Short-term investments $1.63B$1.61B$1.30B$1.60B$1.46B$521.7M$0———
Receivables $0$25.0M$200.0M$0$305.0K$144.0K$99.0K$88.0K$2.6M$3.2M
Total current assets $1.99B$1.94B$1.91B$1.85B$2.42B$1.72B$987.5M$466.4M$248.4M$320.2M
Property, plant and equipment $115.9M$134.1M$151.9M$163.6M$137.6M$42.2M$31.3M$18.5M$18.9M$21.0M
Other intangibles —$0$16.0K$71.0K$125.0K$180.0K$235.0K$289.0K$344.0K$399.0K
Total assets $2.27B$2.24B$2.23B$2.24B$2.75B$1.83B$1.07B$489.0M$271.3M$345.0M
Accounts payable $11.1M$14.7M$38.1M$27.4M$14.8M$9.1M$5.9M$5.1M$1.6M$4.6M
Total current liabilities $149.1M$87.8M$108.8M$121.1M$119.9M$94.3M$57.1M$27.7M$14.5M$22.0M
Total liabilities $343.4M$310.0M$346.8M$367.6M$352.4M$163.7M$127.3M$96.8M$83.5M$112.1M
Retained earnings -$1.95B-$1.37B-$999.7M-$846.1M-$195.9M-$573.6M-$224.7M-$291.6M-$125.4M-$57.1M
Total equity $1.92B$1.93B$1.88B$1.88B$2.40B$1.66B$939.4M$392.2M$187.8M$232.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$345.0M-$142.8M-$260.4M-$495.7M$539.0M-$238.4M$56.7M-$96.2M-$70.1M-$52.9M
Depreciation and amortisation $19.5M$19.3M$19.8M$24.2M$18.0M$9.2M$4.7M$3.5M$3.0M$925.0K
Stock-based compensation $72.5M$86.6M$81.0M$97.9M$102.4M$66.0M$44.1M$35.0M$18.9M$10.8M
Capital expenditure $914.0K$1.9M$9.5M$37.2M$81.7M$18.4M$6.7M$2.8M$7.8M$3.0M
Investing cash flow -$31.8M-$280.5M$374.6M-$258.7M-$1.04B-$541.2M$1.3M-$2.8M-$8.3M$31.9M
Financing cash flow $426.0M$332.0M$62.7M$38.6M$250.9M$1.02B$431.0M$315.9M$2.6M$183.2M
Buybacks ———————$57.0K——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-165158.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B -500M 0 500M 1B Revenue, FY2016: 5.2M Net income, FY2016: -23.2M Revenue, FY2017: 41M Net income, FY2017: -68.4M Revenue, FY2018: 3.1M Net income, FY2018: -165M Revenue, FY2019: 289.6M Net income, FY2019: 66.9M Revenue, FY2020: 719K Net income, FY2020: -348.9M Revenue, FY2021: 915M Net income, FY2021: 377.7M Revenue, FY2022: 1.2M Net income, FY2022: -650.2M Revenue, FY2023: 371.2M Net income, FY2023: -153.6M Revenue, FY2024: 37.3M Net income, FY2024: -366.3M Revenue, FY2025: 3.5M Net income, FY2025: -581.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $5.2M $41.0M $3.1M $289.6M $719.0K $915.0M $1.2M $371.2M $37.3M $3.5M
Gross profit — — — — — — — — — —
Net income -$23.2M -$68.4M -$165.0M $66.9M -$348.9M $377.7M -$650.2M -$153.6M -$366.3M -$581.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%